TEIJINHuman Chemistry, Human Solutions

Teijin Pharma Limited GLOBAL

  • Site Map
  • Contact Us
  • Enlarge Text

menu

  • About Us
  • Our Business Structure
  • Site Map
  • Contact Us

About Us:TOP

  • Corporate Philosophy
  • Message from the President
  • Group Synergies
  • Office Locations
  • Alliance Partners
  • History
  • Corporate Social Responsibility
  • Project Stories
  • News

Our Business Structure:TOP

Business Fields
  • About Teijin Pharma
Business Activities
  • Research & Development
  • Industrial Technology
  • Regulatory Compliance

  • Japan Local Site日本

Home > News Release > 2017

News Release

2017

Nov. 16, 2017
  • Teijin Pharma and SRETT Sign Exclusive Distribution Agreement for Respiratory Remote-monitoring Device
Oct. 26, 2017
  • Teijin Nakashima Medical to Acquire Spinal-related Business of Century Medical
Oct. 16, 2017
  • Teijin Acquires Exclusive Sales Rights to Transcranial Magnetic Stimulation Device in Japan
Oct. 12, 2017
  • Teijin Signs Exclusive License and Co-Development Agreement for Novel Botulinum Toxin in Japan
Jul. 18, 2017
  • JCR and Teijin to Develop Allogeneic Regenerative Medical Product Using Dental Pulp Stem Cells (DPCs)
Jul. 03, 2017
  • Somatuline® Autogel® 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors
May. 26, 2017
  • Teijin Pharma to Enter into Worldwide License Agreement with Merck & Co., Inc., for Investigational Antibody Candidate Targeting Tau

Page Top


News Release

  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • Notice

We use cookies to help improve your experience on our website. Clink on "Agree" to agree and proceed, or click on "See Details" for more information and settings of cookies.

See Details
  • Terms & Conditions of Use
  • Privacy Policy

Copyright © Teijin Pharma Limited. All Rights Reserved.